Eli Lilly Partners With InnoCare on $3.35 Billion Drug Discovery Deal
Deals·2 articles across 2 outlets
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
Eli Lilly has committed $100 million in upfront and near-term payments to InnoCare Pharma to form a five-target drug discovery pact. The deal features up to $3.25 billion in milestones.
This partnership with China's InnoCare represents a significant investment in drug discovery, with the total deal value reaching up to $3.35 billion.
Eli LillyInnoCare
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“Eli Lilly is partnering with China's InnoCare on a drug deal worth up to $3.35 billion”
quartz — Eli Lilly is partnering with China's InnoCare on a drug deal worth up to $3.35 billion“Eli Lilly has committed $100 million in upfront and near-term payments to InnoCare Pharma to form a five-target drug discovery pact.”
fierce biotech — <a href="/biotech/eli-lilly-puts-100m-plus-billions-backend-form-5-target-deal-innocare" hreflang="en">Lilly puts up $100M, plus billions on the backend, to form 5-target deal with China's InnoCare</a>